Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression following beta-catenin stabilization in synovial sarcomagenesis

ABSTRACT: Synovial sarcoma is a deadly soft-tissue malignancy with a predilection for adolescents and young adults. Mice recapitulate synovial sarcomagenesis from expression of SS18-SSX2 in certain cells. Concomitant expression of a stabilized form of beta-catenin enhances synovial sarcomagenesis and expands the potential cells of origin. Mice bearing conditional expression of SS18-SSX2 from the Rosa26 locus and conditional excision of the 3rd exon of beta-catenin, each activated in the leg by Cre-recombinase expressed from an adeno-associated viral vector, formed large tumors at brief latency.

ORGANISM(S): Mus musculus

SUBMITTER: Kevin Jones

PROVIDER: E-GEOD-47388 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Expression following beta-catenin stabilization in synovial sarcomagenesis

Project description:Synovial sarcoma is a deadly soft-tissue malignancy with a predilection for adolescents and young adults. Mice recapitulate synovial sarcomagenesis from expression of SS18-SSX2 in certain cells. Concomitant expression of a stabilized form of beta-catenin enhances synovial sarcomagenesis and expands the potential cells of origin.

2015-11-04 | GSE47388 | GEO

PTEN-deficient synovial sarcoma

Project description:Transcriptome comparisons by RNAseq of genetically engineered mouse models of synovial sarcoma, expressing SS18-SSX1 or SS18-SSX2 and having homozygous conditional genetic silencing of Pten or wildtype Pten.

2016-11-03 | GSE81476 | GEO

Global Identification of SYT-SSX2 Downstream Genes using Human Pluripotent Stem Cells

Project description:We established human pluripotent stem cell (PSC) lines expressing Synovial Sarcoma-specific oncogene, SYT-SSX2, under the control of doxycycline with dose- and time-dependent manner. Gene expression profiles were analyzed to identify early response genes of SYT-SSX2. SYT-SSX2-inducible PSC lines including two hESCs and one hiPSC were analyzed at several time points (0, 6, 12, 18, 24 hours) after doxycycline treatment.

2013-01-30 | E-GEOD-43080 | biostudies-arrayexpress

Mus musculus

Project description:Expression following beta-catenin stabilization in synovial sarcomagenesis

| PRJNA205392 | ENA

Transcription profiling of synovial sarcoma-like tumors induced in a genetically engineered mouse model

Project description:Synovial sarcoma-like tumors were generated in mice by conditionally expressing the human t(X;18) translocation-derived SYT-SSX2 fusion protein. Using a Tamoxifen-inducible CreER system, we show here that sporadic expression of SYT-SSX2 across multiple tissue types leads to exclusive formation of synovial sarcoma-like tumors while its widespread expression is lethal. CreER-based sporadic expression both avoids the severe early developmental phenotypes associated with widespread SYT-SSX2 expression and better models natural pathogenesis of cancers where transformed cells usually arise within an environment of largely normal cells. Experiment Overall Design: Genetically engineered mice capable of conditionally expressing the human synovial sarcoma-associated SYT-SSX2 fusion oncogene were mated with genetically engineered mice expressing the CreER fusion protein from ROSA locus. The progenies harboring both CreER and SYT-SSX2 were followed up with or without tamoxifen injection. Tumors were generated in these mice that were dissected out, RNA extracted, and subjected to expression profiling by microarray analysis.

2009-04-24 | E-GEOD-14469 | biostudies-arrayexpress

Expression data from synovial sarcoma-like tumors induced in a genetically engineered mouse model

2009-04-14 | GSE14469 | GEO

Global Identification of SYT-SSX2 Downstream Genes using Human Pluripotent Stem Cells

2013-01-30 | GSE43080 | GEO

Gene expression profile of SYT-SSX2-expressing C2C12 myoblasts

Project description:Synovial sarcoma is a rare malignancy characterized by the presence of a specific chromosomal translocation t(X;18) that results in the formation of a fusion protein SYT-SSX. Because it is believed that synovial sarcoma arises from mesenchymal stem or progenitor cells, we wanted to determine the changes in gene expression caused by SYT-SSX2 in untransformed mesenchymal progenitor cells - murine C2C12 myoblasts in this experiment. In 2 independent experiments, C2C12 myoblasts were infected with retrovirus carrying either control vector (pOZ) or SYT-SSX2 expression vector. Total cellular RNA was extracted 48 hours post-infection and utilized for microarray analysis on Affymetrix arrays.

2011-09-25 | E-GEOD-26562 | biostudies-arrayexpress

Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2

Project description:Cellular identity is determined by its gene expression programs. The ability of the cell to change its identity and produce cell types outside its lineage is achieved by the activity of transcription controllers capable of reprogramming differentiation gene networks. The synovial sarcoma associated protein, SYT-SSX2, reprograms myogenic progenitors and human bone marrow-derived mesenchymal stem cells (BMMSCs) by dictating their commitment to a pro-neural lineage. It fulfills this function by directly targeting an extensive array of neural-specific genes as well as genes of developmental pathway mediators. Concomitantly, the ability of both myoblasts and BMMSCs to differentiate into their normal myogenic and adipogenic lineages was compromised. Synovial sarcoma is believed to arise in mesenchymal stem cells where formation of the t(X;18) translocation product, SYT-SSX, constitutes the primary event in the cancer. SYT-SSX is therefore believed to initiate tumorigenesis in its target stem cell. The data presented here allow a glimpse at the initial events that likely occur when SYT-SSX2 is first expressed and its dominant function in subverting the nuclear program of the stem cell, leading to its aberrant differentiation, as a first step toward transformation. In addition, we identified the fibroblast growth factor receptor gene, Fgfr2, as one occupied and upregulated by SYT-SSX2. Knockdown of FGFR2 in both BMMSCs and synovial sarcoma cells abrogated their growth and attenuated their neural phenotype. These results support the notion that the SYT-SSX2 nuclear function and differentiation effects are conserved throughout sarcoma development and are required for its maintenance beyond the initial phase. They also provide the stem cell regulator, FGFR2 as a promising candidate target for future synovial sarcoma therapy. Refer to individual Series

2011-09-25 | E-GEOD-26565 | biostudies-arrayexpress

GENE EXPRESSION ANALYSIS OF SYNOVIAL BIOPSIES AND PERIPHERAL BLOOD SAMPLES FROM PSORIATIC ARTHRITIS

Project description:Gene expression profiles of synovial biopsies and peripheral blood cells from Psoriatic Arthritis were compared to gene expression profiles of synovial samples and peripheral blood cells from healthy subjects.

2015-12-22 | E-MTAB-3201 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data